Sunshine Biopharma Inc. Net Income (Loss), Including Portion Attributable to Noncontrolling Interest
Sunshine Biopharma Inc. (SBFM) reported Net Income (Loss), Including Portion Attributable to Noncontrolling Interest of -$1.46 million for the 3-month period ending 2022-09-30, per its 10-Q filed 2022-11-07.
Discontinued › Income Statement › Net Income
us-gaap:ProfitLoss · last filed 2022-11-07
- Sunshine Biopharma Inc. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2022-09-30 was -$1.46M.
- Sunshine Biopharma Inc. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2022-06-30 was -$538.87K.
- Sunshine Biopharma Inc. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2022-03-31 was -$1.24M.
- Sunshine Biopharma Inc. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2021-12-31 was $646.85K.
- Sunshine Biopharma Inc. net income (loss), including portion attributable to noncontrolling interest for fiscal 2021 was -$12.46M.
- Sunshine Biopharma Inc. net income (loss), including portion attributable to noncontrolling interest for fiscal 2020 was -$2.78M.
- Sunshine Biopharma Inc. net income (loss), including portion attributable to noncontrolling interest for fiscal 2019 was -$1.66M.
- Sunshine Biopharma Inc. net income (loss), including portion attributable to noncontrolling interest for fiscal 2018 was -$2.16M.
| Period end | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 3 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 3 month as first filed | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 6 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 6 month as first filed | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 9 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 9 month as first filed | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 12 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2022-09-30 | -$1.46M 10-Q · filed 2022-11-07 | -$2.00M derived: sum of 2 quarters · filed 2022-11-07 | -$3.23M 10-Q · filed 2022-11-07 | -$2.59M derived: sum of 4 quarters · filed 2022-11-07 | ||||
| 2022-06-30 | -$538.87K 10-Q · filed 2022-08-03 | -$1.78M 10-Q · filed 2022-08-03 | -$1.13M derived: sum of 3 quarters · filed 2022-08-03 | -$5.17M derived: sum of 4 quarters · filed 2022-11-07 | ||||
| 2022-03-31 | -$1.24M 10-Q · filed 2022-05-06 | -$589.39K derived: sum of 2 quarters · filed 2022-05-06 | -$4.63M derived: sum of 3 quarters · filed 2022-11-07 | -$7.51M derived: sum of 4 quarters · filed 2022-11-07 | ||||
| 2021-12-31 | $646.85K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-21 | -$3.39M derived: sum of 2 quarters · filed 2022-11-07 | -$6.27M derived: sum of 3 quarters · filed 2022-11-07 | -$12.46M 10-K · filed 2022-03-21 | ||||
| 2021-09-30 | -$4.04M 10-Q · filed 2022-11-07 | -$4.05M 10-Q · filed 2021-11-09 | -$6.92M derived: sum of 2 quarters · filed 2022-11-07 | -$13.10M 10-Q · filed 2022-11-07 | -$13.12M 10-Q · filed 2021-11-09 | -$14.19M derived: sum of 4 quarters · filed 2022-11-07 | ||
| 2021-06-30 | -$2.88M 10-Q · filed 2022-08-03 | -$2.89M 10-Q · filed 2021-08-09 | -$9.06M 10-Q · filed 2022-08-03 | -$9.07M 10-Q · filed 2021-08-09 | -$10.15M derived: sum of 3 quarters · filed 2022-08-03 | -$10.85M derived: sum of 4 quarters · filed 2022-08-03 | ||
| 2021-03-31 | -$6.19M 10-Q · filed 2022-05-06 | -$6.19M 10-Q · filed 2021-05-11 | -$7.27M derived: sum of 2 quarters · filed 2022-05-06 | -$7.97M derived: sum of 3 quarters · filed 2022-05-06 | -$8.87M derived: sum of 4 quarters · filed 2022-05-06 | |||
| 2020-12-31 | -$1.08M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-21 | -$1.78M derived: sum of 2 quarters · filed 2022-03-21 | -$2.69M derived: sum of 3 quarters · filed 2022-03-21 | -$2.78M 10-K · filed 2022-03-21 | -$2.78M 10-K · filed 2021-03-30 | |||
| 2020-09-30 | -$698.74K 10-Q · filed 2021-11-09 | -$1.61M derived: sum of 2 quarters · filed 2021-11-09 | -$1.70M 10-Q · filed 2021-11-09 | -$2.10M derived: sum of 4 quarters · filed 2021-11-09 | ||||
| 2020-06-30 | -$906.97K 10-Q · filed 2021-08-09 | -$637.84K 10-Q · filed 2020-08-19 | -$1.00M 10-Q · filed 2021-08-09 | -$733.44K 10-Q · filed 2020-08-19 | -$1.40M derived: sum of 3 quarters · filed 2021-08-09 | -$1.75M derived: sum of 4 quarters · filed 2021-08-09 | ||
| 2020-03-31 | -$95.60K 10-Q · filed 2021-05-11 | -$493.82K derived: sum of 2 quarters · filed 2021-05-11 | -$844.17K derived: sum of 3 quarters · filed 2021-05-11 | -$1.55M derived: sum of 4 quarters · filed 2021-05-11 | ||||
| 2019-12-31 | -$398.22K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-30 | -$748.57K derived: sum of 2 quarters · filed 2021-03-30 | -$1.46M derived: sum of 3 quarters · filed 2021-03-30 | -$1.66M 10-K · filed 2021-03-30 | ||||
| 2019-09-30 | -$350.36K 10-Q · filed 2020-11-12 | -$350.24K 10-Q · filed 2019-11-13 | -$1.06M derived: sum of 2 quarters · filed 2020-11-12 | -$1.26M 10-Q · filed 2020-11-12 | -$1.26M 10-Q · filed 2019-11-13 | -$1.60M derived: sum of 4 quarters · filed 2020-11-12 | ||
| 2019-06-30 | -$708.39K 10-Q/A · filed 2020-08-31 | -$710.89K 10-Q · filed 2019-08-15 | -$911.72K 10-Q/A · filed 2020-08-31 | -$900.09K 10-Q · filed 2019-08-15 | -$1.25M derived: sum of 3 quarters · filed 2020-08-31 | -$2.16M derived: sum of 4 quarters · filed 2020-08-31 | ||
| 2019-03-31 | -$203.33K 10-Q · filed 2020-05-18 | -$541.98K derived: sum of 2 quarters · filed 2020-05-18 | -$1.45M derived: sum of 3 quarters · filed 2020-05-18 | -$2.09M derived: sum of 4 quarters · filed 2020-05-18 | ||||
| 2018-12-31 | -$338.65K derived: 10-K 12 month − 10-Q 9 month · filed 2020-05-01 | -$1.25M derived: sum of 2 quarters · filed 2020-05-01 | -$1.89M derived: sum of 3 quarters · filed 2020-05-01 | -$2.16M 10-K · filed 2020-05-01 | -$2.16M 10-K · filed 2019-04-12 | |||
| 2018-09-30 | -$907.56K 10-Q · filed 2019-11-13 | -$1.55M derived: sum of 2 quarters · filed 2019-11-13 | -$1.82M 10-Q · filed 2019-11-13 | |||||
| 2018-06-30 | -$644.31K 10-Q · filed 2019-08-15 | -$909.94K 10-Q · filed 2019-08-15 | ||||||
| 2018-03-31 | -$265.64K 10-Q · filed 2019-05-20 | |||||||
| 2017-12-31 | -$1.04M 10-K · filed 2019-04-12 | |||||||
| 2016-12-31 | -$3.50M 10-K · filed 2018-04-02 | -$3.50M 10-K · filed 2017-04-17 | ||||||
| 2015-12-31 | -$1.65M 10-K · filed 2017-04-17 | |||||||
| 2014-12-31 | -$1.93M 10-K · filed 2016-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Onconetix, Inc. (ONCO) | United States | $0.004B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| HCW Biologics Inc. (HCWB) | United States | $0.004B | -6.15 |
| REVELATION BIOSCIENCES, INC. (REVB) | United States | $0.004B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B |